⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TNXP News
Tonix Pharmaceuticals Holding Corp.
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
globenewswire.com
TNXP
Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
globenewswire.com
TNXP
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
globenewswire.com
TNXP
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
globenewswire.com
TNXP
Form 8-K
sec.gov
TNXP
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
globenewswire.com
TNXP
Form 8-K
sec.gov
TNXP
Form 8-K
sec.gov
TNXP